AgenT is developing a blood test that utilizes machine learning and multiomics biomarkers to detect Alzheimer's disease up to 20 years before the onset of irreversible symptoms. This early detection aims to identify molecular changes in the brain, enabling timely intervention and potential prevention of the disease.
Funding
$2.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current diagnostic tools for Alzheimer's disease often detect the condition too late, after irreversible brain damage has already occurred. This late detection limits the potential for effective intervention and prevention of symptom onset or disease progression.
Solution
AgenT is developing a blood test that leverages machine learning and multiomics biomarkers to detect Alzheimer's disease in its early stages, potentially up to 20 years before the onset of irreversible symptoms. The test analyzes proteins and metabolites circulating in blood plasma to identify the body's response to Alzheimer's disease. By detecting the disease during its silent phase, AgenT aims to enable timely intervention and potentially prevent the progression of Alzheimer's. The company envisions integrating this blood test into routine health screenings, similar to current cancer screening practices.
Target Audience
The primary target audience includes physicians and healthcare providers seeking early diagnostic tools for Alzheimer's disease, as well as individuals at risk of developing the condition.
Features
- Multiomics biomarker analysis of blood plasma
- Machine learning algorithms to decode the body's response to Alzheimer's disease
- Early detection of Alzheimer's disease, potentially up to 20 years before irreversible symptoms